Cameroon became the first African country to receive the Mosquirix malaria vaccine for use as a fully tested preventive in a ...

The number of malaria cases rose again in 2022, propelled by flooding and warmer weather in areas once free of the illness.

Health Sector Performance Report for 2022/2023 revealed major causes of deaths, with malaria on top, accounting for 4,245 ...

The second vaccine, R21/Matrix-M, is highly effective, reducing cases of malaria by 75%. Hundreds of millions of doses of this vaccine can be produced each year. It will be ready for rollout as ...

Rose Leke does not work for, consult, own shares in or receive funding from any company or organization that would benefit ...

As the clock ticked toward midnight on the night of Nov. 21 in Yaoundé, Cameroon, aid workers began unloading 331,200 doses ...

Malaria burden is the highest on the African continent, which accounts for approximately 95% of global malaria cases and 96 ...

More than 330,000 doses of the Mosquirix malaria vaccine have been delivered to Cameroon as part of efforts to ramp up ...

Cameroon received its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker GSK Plc late on Tuesday, ...

The RTS,S construct formulated with the adjuvant AS02 gave approximately 50% protection from clinical malaria in a Phase IIa trial. Field trials ensued with an efficacy of 30–60% in a 6–12 ...

The approval of two malaria vaccines—the RTS,S/AS01 vaccine in 2021 and the R21/Matrix-MTM vaccine in 2023—will help control, and eventually help eradicate, a disease that causes more than ...